| Suellen M. Curkendall, 2004, Saskatchewan Canada, cohort study, not described. (article 1)1515 Curkendall SM, Mo J, Glasser DB, Rose Stang M, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry. 2004; 65(5):715-20.
|
General population and patients with schizophrenia |
47 ± SD |
January 1996 to March 1999 |
Group 1. General population (n=12,088)
Patients with schizophrenia (n=3,022)
Group 2. General population (n=9,175)
Patients with schizophrenia (n=2,405) |
The population of patients with schizophrenia was prescribed: phenothiazine, haloperidol and risperidone. These data were obtained from governmental health database records. Home interviews and a medical examination at the local health center or an interview and exam health at home were carried out |
(1) Identification of diseases by ICD 09. (2) Validation in databases. (3) Adjustments to CV risk factors limited to administrative data. (4) Patients treated exclusively by a psychiatrist were not likely to be identified for the study unless they were hospitalized |
AMI Arrhythmia Mortality |
AMI: 0.9 (95CI 0.6-1.4)
Arrhythmia: adjustedrelative risk 1.5 (95CI 1.2-1.8)
Mortality: adjusted relative risk 2.2 (95CI 1.7-2.8) |
| Jaana Suvisaari, 2010, Finland, cohort study, approved by the Hospital District of Helsinki and Uusimaa Ethics Committee, and participants signed consent. (article 2)1616 Suvisaari J, Perälä J, Saarni SI, Kattainen A, Lönnqvist J, Reunanen A. Coronary heart disease and cardiac conduction abnormalities in persons with psychotic disorders in the general population. Psychiatry Res. 2010; 175(1-2):126-32.
|
Patients with schizophrenia, ONAP and affective psychosis |
53 ± SD |
September 2000 to June 2001 |
Without CV disease
1. Without psychotic disorder (n=53)
2. ONAP (n=69) With CV disease
1. Without psychotic disorder (n=857)
2. Schizophrenia (n=8)
3. ONAP (n=10) |
Chlorprothixene, methotrimeprazine, chlorpromazine, promazine, melperone, sulpiride, flunarizine, haloperidol, flupenthixol, zuclopenthixol, pericyazine, perphenazine and atypical (clozapine, olanzapine, risperidone, quetiapine, amitriptyline, clomipramine, imipramine, doxepin, nortriptyline, and trimipramine). Identified data via of household interviews |
(1) A small number of cases. (2) Limiting the statistical power. (3) Electrocardiogram not monitored long enough. (4) Dosage of the unregistered medication |
AMI Arrhythmia |
AMI: 95CI 5.4-63.5
Arrhythmia: 95CI 6.3-64.6 |
| Josep Darbà, 2013, Spain, cohort study, not described. (article 3)1717 Darbà J, Kaskens L, Aranda P, Arango C, Bobes J, Carmena R, et al. The simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs. Ann Clin Psychiatry. 2013; 25(1):17-26.
|
Patients with schizophrenia and baseline group |
41 ± SD |
10 years |
Group 1. 25,157 patients taking quetiapine
Group 2. 24,883 patients taking risperidone
Group 3. 24,514 patients taking ziprasidone
Group 4. 25,269 patients taking olanzapine
Group 5. 24,900 (baseline) |
Four hypothetical groups were generated, for olanzapine, quetiapine, risperidone and ziprasidone |
(1) Modified risk equation, resulting in a lower incidence of CV events and high risk. (2) Lack of data in clinical trials. (3) Simulates future events, under- or overestimate the actual rate of coronary events |
Mortality |
9,389 assigned to the drug olanzapine, quetiapine drug to 9,341, 9,228 to the drug risperidone and ziprasidone drug to 9,074 |
